ArticleJournal of cheminformatics2025
UMAP-based clustering split for rigorous evaluation of AI models for virtual screening on cancer cell lines.
Article in Journal of cheminformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Artificial Intelligence-Guided Phenotypic Drug Repurposing Against Streptococcus pneumoniae.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- TRPM8 virtual screening: the essential role of target-specific, inactive-enriched machine-learning scoring functions.Digital discovery · 2026Article
- Article
- Cardiosim-Tox: an interpretable multitask deep learning QSAR platform with multimodal feature fusion for predicting hERG, Cav1.2, and Nav1.5 blockade risk and potency.Archives of toxicology · 2026Article
- Trust Beyond Accuracy: Conformal Uncertainty Quantification Reveals the Generalization Gap in Polymer Glass Transition Temperature Prediction.ACS omega · 2026Article
- Article
- Empowering chemical structures with biological insights for scalable phenotypic virtual screening.Bioinformatics (Oxford, England) · 2026Article
- Research trends in cytokine regulation of immunotherapy in non-small cell lung cancer: a bibliometric and BERTopic analysis from 2015 to 2025.Journal of thoracic disease · 2026Article
- Discovery of mitochondrial modulators using target-aggregated machine learning.Journal of pharmaceutical analysis · 2026Article
- Deep Learning for Anticancer Drug Discovery Targeting Non-Apoptotic Regulated Cell Death Mechanisms.Pharmaceuticals (Basel, Switzerland) · 2026Review
- A Systematic Survey and Benchmark of Deep Learning for Molecular Property Prediction in the Foundation Model Era.Journal of chemical theory and computation · 2026Review
- A Leakage-Aware Drug Discovery Workflow for PKM2 and MAPK1 Integrating Scaffold Validation, Molecular Docking and Structural Triage.International journal of molecular sciences · 2026Article
- Artificial intelligence for antimicrobial resistance: advancing reproducibility, interpretability, and clinical deployment.Briefings in bioinformatics · 2026Review
- From Algorithms to Assets: A Comprehensive Review of AI's Role in Preclinical Drug Discovery and the Hurdles to Clinical Translation.Pharmaceuticals (Basel, Switzerland) · 2026Review
- AI-driven drug-target interaction prediction: current progress, challenges, and future roadmap for precision medicine.Journal of computer-aided molecular design · 2026Review
- Defining the Data set Defines the QSAR Claim.Journal of chemical information and modeling · 2026Article
- Benchmarking community drug response prediction models: datasets, models, tools, and metrics for cross-dataset generalization analysis.Briefings in bioinformatics · 2026Article
- How to build machine learning models able to extrapolate from standard to modified peptides.Journal of cheminformatics · 2025Article
- Pharmacogenomic Drug-Target Network Analysis Reveals Similarity Profiles Among FDA-Approved Cancer Drugs.Pharmaceutics · 2025Article
- Evaluating Machine Learning Models for Molecular Property Prediction: Performance and Robustness on Out-of-Distribution Data.Journal of chemical information and modeling · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Virtual Screening (VS) of large compound libraries using Artificial Intelligence (AI) models is a highly effective approach for early drug discovery. Data splitting is crucial for benchmarking the performance of such AI models. Traditional random data splits often result in structurally similar molecules in both training and test sets, which conflict with the reality of VS libraries that typically contain structurally diverse compounds. To tackle this challenge, scaffold split, which groups molecules by shared core structure, and Butina clustering, which clusters molecules by chemotypes, have long been used. However, we show that these methods still introduce high similarities between training and test sets, leading to overestimated model performance. Our study examined four representative AI models across 60 NCI-60 datasets, each comprising approximately 33,000-54,000 molecules tested on different cancer cell lines. Each dataset was split in four ways: random, scaffold, Butina clustering and the more realistic Uniform Manifold Approximation and Projection (UMAP) clustering. Using Linear Regression, Random Forest, Transformer-CNN, and GEM, we trained a total of 8400 models and evaluated under four splitting methods. These comprehensive results show that UMAP split provides more challenging and realistic benchmarks for model evaluation, followed by Butina splits, then scaffold splits and closely after random splits. Consequently, we recommend using UMAP splits instead of overly optimistic Butina splits and especially scaffold splits for molecular property prediction, including VS. Lastly, we illustrate how misaligned ROC AUC is with VS goals, despite its common use. The code and datasets for reproducibility are available at https://github.com/Rong830/UMAP_split_for_VS and archived in https://zenodo.org/records/14736486 . Scientific contribution This work advances the field by introducing UMAP clustering as a robust splitting method for molecular datasets, improving over traditional methods like Butina clustering and especially scaffold splits. It offers a new evaluation framework to benchmark AI models under more realistic conditions, fostering progress in molecular property prediction. The findings also show how inappropriate the use of ROC AUC for virtual screening (VS) continues to be, despite its popularity, emphasizing the need for context-specific evaluation metrics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.